Biology Atlas

Map / Modalities

modality · intermediate · partly written

Stem cell therapy

Stem cell therapy puts living cells into a person to replace or rebuild a tissue; the hard parts are placing them, keeping them alive and not having them rejected.

Also called: cell therapy, cell replacement therapy, regenerative cell therapy

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

The short version

Replacing cells is the goal, not the method. The cells have to reach the right place, stay and work, and not be destroyed by the recipient's immune system. Own cells avoid rejection; donor cells need immune-suppressing drugs or a genetic edit. Surviving is not enough: fetal brain grafts survived and still failed. 123

Reported, not yet replicated

Is it surgery with a knife?

Sometimes, and often not. Brain tissue went in by neurosurgery through a hole in the skull; Holoclar is placed on the eye by a surgeon; but donor islets go through a catheter into a liver vein, and cord blood stem cells by drip. In none of these is the old tissue cut out and swapped back. 4125

Reported, not yet replicated

How the cells are physically placed more

The route follows the tissue.

Eye: a trained eye surgeon implants the cultured sheet grown on a fibrin membrane (fibrin is the clotting protein, used as a carrier).

Liver: a catheter delivers islets into the hepatic portal vein; the FDA reports a median peak rise in portal pressure of 3 mmHg (range -3 to 18) because the islets microembolize the small vessels.

Brain: tissue was implanted into the putamen on both sides after drilling holes in the skull.

Muscle: edited donor islets were put into the forearm muscle of one man, an arrangement chosen in that report.

Blood: a cord blood product is infused for patients already planned for transplant after myeloablative conditioning. 12465

Reported, not yet replicated

How they are made to stay (engraftment) more

There is no biological glue to apply. Three things keep cells where they are put: mechanical lodging (islets stuck in liver vessels), the right niche (a stem cell product on the surface it normally renews), and protection from the immune system. For blood stem cells, the marrow has to be prepared by conditioning before the donor cells go in: the FDA page says omidubicel is for patients planned for cord blood transplant after myeloablative conditioning. Cells can also be given a dose big enough to survive early loss; in the first Edmonton series, a mean of 11,547 islet equivalents per kilogram, from two donor pancreases for every patient, was needed for insulin independence. 572

Reported, not yet replicated

Why conditioning is used deep

The usual explanation is that conditioning with chemotherapy or radiation empties marrow niches occupied by the recipient's own stem cells and also suppresses the recipient's immune cells, so donor cells can settle. The review that makes this point was blocked and its text was not opened here, so this explanation is marked unverified; what was opened is only that the product is given after myeloablative conditioning. 5

Unverified: from our own report, source not opened

What Amit said and asked about it

He said: "Stem cell therapy, which just replaces the cells." He asked: "How do you replace those cells, actually? Is it just a surgery where you just literally go in with a knife, cut things out, and put them back in? How do you glue it in there so it sticks?" 8

Amit's hypothesis

What the evidence says about the guess and the questions more

"Just replaces the cells" is the goal and is roughly right, but it hides two hard problems: which cells, and whether they stay and work. The answers to his questions: it is sometimes surgery (brain, eye) but often a catheter or a drip; nothing is cut out and put back; there is no glue, cells stay by lodging, homing, the niche they belong in, and being kept away from the immune system.

Rejection follows from whose cells they are. A patient's own cells carry the patient's own HLA tags, so no alloimmune rejection is expected in principle (a review notes autologous cells are compatible in principle, with person-to-person variation and cost as drawbacks). Donor cells carry foreign HLA. In Lantidra the FDA states that immunosuppression is required for beta-cell survival, and that stopping it loses the islets. 912

Reported, not yet replicated

Three ways round rejection more

1. Use the patient's own cells (autologous): Holoclar may only be given to the patient whose cells made it.

2. Suppress the recipient's immune system with drugs: Lantidra, and the glucocorticoid-free regimen of sirolimus, tacrolimus and daclizumab used in the first Edmonton series. The cost: in Lantidra's studies, serious infections in 83 percent, 16 malignancy events in 11 of 30 subjects, and eight subjects who had to stop the drugs because of severe infection.

3. Make the cells hard for the immune system to see. Cells from HLA-homozygous donors or genetically modified to deplete HLA are under study; natural killer cells attack cells that lack self HLA class I (missing self), so deleting HLA is not a simple fix. In one reported case, gene-edited donor islets put into one man's forearm muscle without immunosuppression showed no immune response against them at 12 weeks and stable, glucose-responsive insulin secretion, with four adverse events, none serious. One participant, 12 weeks: this is proof of concept only. 12796

Reported, not yet replicated

Surviving is not the same as working deep

Three cases show why. Donor islets live and still decline: of 65 Edmonton patients at 5 years about 80 percent still had C-peptide but only about 10 percent kept insulin independence. Fetal dopamine neurons lived and still harmed: 56 percent of transplanted patients in one trial developed off-medication dyskinesia and the primary endpoint was not met. Holoclar works for a thin, flat, self-renewing surface where a few cells do a structural job, with the patient's own cells: 72 percent of 104 patients were judged successful at one year in a retrospective study, but a prospective study gave 36.2 percent, so the evidence is graded, not absolute. 103111

Reported, not yet replicated

The next generation: stem cell-derived islets deep

Zimislecel is an allogeneic stem cell-derived islet product given by a single infusion into the portal vein together with glucocorticoid-free immunosuppression. In an interim, non-prespecified phase 1-2 analysis, 14 participants completed 12 months; all had detectable C-peptide, none at baseline. All 12 full-dose participants were free of severe hypoglycemic events with HbA1c below 7 percent, and 10 of 12 (83 percent) were insulin independent at day 365. Two deaths occurred, one from cryptococcal meningitis and one from severe dementia with agitation owing to progression of preexisting neurocognitive impairment. The authors call the study small and short-term; the sponsor funded it. Whether the meningitis was judged related to immunosuppression was not in the abstract read. 12

Reported, not yet replicated

What it is

The medicine is living cells. They can be the patient's own (autologous, as in Holoclar, made from the patient's limbal stem cells), a donor's (allogeneic, as in Lantidra, made from deceased donor pancreas islets), or cells grown from stem cells in the laboratory (zimislecel, stem cell-derived islets, in a phase 1-2 study). Fetal brain tissue was a donor tissue version of the idea. 12124

Reported, not yet replicated

Intervenes at

Same as small molecule

The questions are the same ones: is there a disease mechanism to fix, does the medicine get to the right place, how do we measure that it worked, and what harm does it cause. Regulators still judge benefit against risk in a defined group of patients, as the FDA did for Lantidra by weighing insulin independence against the risks of immunosuppression. 2

Our inference

Changes downstream

The product is alive and cannot be taken apart for testing the way a molecule can. Making it: Holoclar is made from a biopsy of 1-2 mm2 for one patient only; Lantidra is made lot by lot from a deceased donor pancreas. Testing it: potency is a property of the cells, for example the share of p63-bright stem cells in a Holoclar culture, which was linked to outcome in a post hoc analysis, and engraftment of islets is read from C-peptide. Dosing: a cell dose is counted in cells, not milligrams. Trials are often small and single-arm, and the endpoint can mislead: the FDA called Lantidra's primary composite endpoint not interpretable. No treatment advice is given here. 113212

Reported, not yet replicated

Delivery

Placement follows where the cells must live. Eye: a surgeon places a cultured sheet on the cornea (Holoclar). Liver: islets are infused by catheter into the portal vein and lodge in small vessels (Lantidra; stem cell-derived islets in the same way in a study). Brain: surgery through the skull, putting tissue into the putamen on both sides (fetal grafts). Muscle: edited donor islets were injected into the forearm of one man. Blood stem cells (cord blood) are infused into a vein after myeloablative conditioning. There is no glue for infused cells: they stay because they lodge mechanically, or home to a niche, or because the surgeon places a sheet where the cells are meant to live, and because the immune system is kept away (the patient's own cells, immunosuppressive drugs, or edited cells). 1212465

Reported, not yet replicated

Persistence

It depends on the product. A stem cell product can keep renewing a tissue: Holoclar restored eyes stayed stable up to 10 years in a case series (mean follow-up under 3 years). Donor islets fade under drugs: after 5 years in 65 Edmonton patients about 10 percent kept insulin independence. It is hard to turn off: stopping immunosuppression loses islets, and a brain graft cannot be switched off once placed, which matters when it causes dyskinesia. 131023

Reported, not yet replicated

Examples

Teach this

In one sentence

Stem cell therapy replaces cells, but the real work is getting them to the right place, keeping them alive and working, and keeping the immune system from destroying them. 12

Reported, not yet replicated

The five-minute version

The medicine is living cells: your own, a donor's or lab-grown. They go in by surgery (brain, eye) or by catheter or drip (islets into a liver vein; blood stem cells into a vein). There is no glue; cells stay by lodging, by homing to a niche, and by escaping the immune system. Own cells are not rejected. Donor cells need immune-suppressing drugs, which cost infections and cancers (Lantidra), or edits that hide the cells (one case reported). Survival is not success: fetal grafts survived and failed. 1236

Reported, not yet replicated

What a listener will ask

Do they cut out the bad cells first?

Not in the cases read here: the new cells are added, with a catheter, a drip or surgery, and nothing is swapped back.

Why are donor cells rejected but my own are not?

Cells carry HLA identity tags; your own match your immune system, a donor's do not.

Does it last?

It varies: Holoclar eyes stayed stable for years in a case series, while insulin independence from donor islets faded over the years in a large series.

The common wrong idea

Stem cell therapy just swaps in new cells, so if they get in, it works.

Cells must be placed, must survive, must function and must not be rejected; three real programmes show survival without success.

The one citation to hand over: 2

Still open here

Linked from

Sources

  1. European Medicines Agency. Holoclar: European public assessment report summary page. EMA (2024). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  2. U.S. Food and Drug Administration. Summary Basis for Regulatory Action: LANTIDRA (donislecel-jujn). FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  3. Olanow, C. W., Goetz, C. G., Kordower, J. H., et al.. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology (2003). paper; opened 2026-11-17 all records citing this
  4. Freed, C. R., Greene, P. E., Breeze, R. E., et al.. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine (2001). paper; opened 2026-11-17 all records citing this
  5. U.S. Food and Drug Administration. FDA approves omidubicel to reduce time to neutrophil recovery and infection in patients with hematologic malignancies. FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  6. Carlsson, P.-O., Hu, X., Scholz, H., et al.. Survival of transplanted allogeneic beta cells with no immunosuppression. New England Journal of Medicine (2025). paper; opened 2026-11-17 all records citing this
  7. Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., et al.. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine (2000). paper; opened 2026-11-17 all records citing this
  8. Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
  9. Flahou, C., Morishima, T., Takizawa, H., et al.. Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Frontiers in Immunology (2021). review; opened 2026-11-17 all records citing this
  10. Ryan, E. A., Paty, B. W., Senior, P. A., et al.. Five-year follow-up after clinical islet transplantation. Diabetes (2005). paper; opened 2026-11-17 all records citing this
  11. Holostem Terapie Avanzate s.r.l. (sponsor). EU Clinical Trials Register: results for EudraCT 2014-002845-23 (HOLOCORE). EU Clinical Trials Register. database, not peer reviewed; opened 2026-11-17 all records citing this
  12. Reichman, T. W., Markmann, J. F., Odorico, J., et al.. Stem cell-derived, fully differentiated islets for type 1 diabetes. New England Journal of Medicine (2025). paper; opened 2026-11-17 all records citing this
  13. Rama, P., Matuska, S., Paganoni, G., et al.. Limbal stem-cell therapy and long-term corneal regeneration. New England Journal of Medicine (2010). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (2)

This record has been changed 2 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/modalities/stem-cell-therapy.json